Simultaneous determination of nucleosides, modified nucleosides and mononucleotides in gastric cancer cells by liquid chromatography coupled with tandem mass spectrometry
Juan Li , Piao Zhou , Manni He , Mengxue Liu , Duo Chen , Hongmin Liu
{"title":"Simultaneous determination of nucleosides, modified nucleosides and mononucleotides in gastric cancer cells by liquid chromatography coupled with tandem mass spectrometry","authors":"Juan Li , Piao Zhou , Manni He , Mengxue Liu , Duo Chen , Hongmin Liu","doi":"10.1016/j.jpba.2025.117177","DOIUrl":null,"url":null,"abstract":"<div><div>Nucleosides and their modified forms serve as fundamental building blocks of nucleic acids and play critical roles in epigenetic regulation, RNA metabolism, and cellular signaling. In this study, we developed and validated a rapid, sensitive ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for the simultaneous quantification of 27 endogenous nucleosides—including 12 canonical nucleosides, 11 modified nucleosides, and 4 mononucleotides—in cellular samples. Under optimized chromatographic conditions, good separations and peak shapes for 27 target compounds were achieved within a 13.0-min gradient elution. The overall LOQs were between 0.2 and 25.0 ng/mL. The intra-day precision of the method was less than 8.2 %, and the inter-day precision was less than 14.2 %. The accuracy was in the range of 89.9–112.2 % for all analytes. The developed method was successfully applied to analyze the metabolic profiles of gastric cancer cells with varying differentiation degrees (NCI-N87, SGC-7901, MGC-803). The results revealed distinct nucleotide metabolism alterations linked to tumor progression and identified potential biomarkers for gastric cancer advancement.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"267 ","pages":"Article 117177"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical and biomedical analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0731708525005187","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Nucleosides and their modified forms serve as fundamental building blocks of nucleic acids and play critical roles in epigenetic regulation, RNA metabolism, and cellular signaling. In this study, we developed and validated a rapid, sensitive ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for the simultaneous quantification of 27 endogenous nucleosides—including 12 canonical nucleosides, 11 modified nucleosides, and 4 mononucleotides—in cellular samples. Under optimized chromatographic conditions, good separations and peak shapes for 27 target compounds were achieved within a 13.0-min gradient elution. The overall LOQs were between 0.2 and 25.0 ng/mL. The intra-day precision of the method was less than 8.2 %, and the inter-day precision was less than 14.2 %. The accuracy was in the range of 89.9–112.2 % for all analytes. The developed method was successfully applied to analyze the metabolic profiles of gastric cancer cells with varying differentiation degrees (NCI-N87, SGC-7901, MGC-803). The results revealed distinct nucleotide metabolism alterations linked to tumor progression and identified potential biomarkers for gastric cancer advancement.
期刊介绍:
This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome.
Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.